Response and resistance to lapatinib in HER2-overexpressing breast cancer

作者
Wing Yin Leung
出处
期刊:University of Oxford - Oxford University Research Archive (ORA) [University of Oxford]
标识
DOI:10.5287/ora-bejm7xv2x
摘要

HER2 overexpression has been implicated in breast cancer. Lapatinib is a dual EGFR/HER2 tyrosine kinase inhibitor used in advanced HER2-positive breast cancer patients who have previously progressed on trastuzumab treatment. Recent meta-analysis of several clinical trials showed that lapatinib was inferior to trastuzumab as a neoadjuvant treatment combined with chemotherapy; however, the mechanism underlying this difference remains unclear. This thesis aimed to assess the acute response and mechanism of resistance to lapatinib in HER2-overexpressing breast cancer cell lines SK-BR-3 and BT-474. Lapatinib inhibited the phosphorylation of EGFR, HER2 and HER3, but it recovered after eight hours of treatment. Lapatinib treatment induced NRG1 expression, correlating with this recovery. Lapatinib-resistant cell lines, SK250LR and BT250LR, were generated. These cells had an increased NRG1 mRNA expression, but the expression levels reduced within a week of lapatinib withdrawal. Exogenous NRG1 rescued breast cancer cells from lapatinib inhibition, because lapatinib only incompletely inhibited NRG1-induced HER3 and HER4 signalling pathways. Combining lapatinib with pertuzumab (L+P) improved the inhibition on NRG1-induced signalling. This difference in inhibitory abilities correlated with the effect of treatment, as L+P induced growth inhibition and apoptosis more than either drug alone. In vivo experiments also showed that L+P triggered greater tumour regression than monotherapy in a BT-474 xenograft model. L+P induced more apoptosis in BT250LR cells but not in SK250LR cells, but it required further validation in a lapatinib-resistant xenograft model. Analysis of RTKs activation suggested that SK250LR and BT250LR cell lines had different mechanisms of resistance. The SK250LR cell line underwent permanent changes in cell biology and became independent from EGFR/HER2 signalling. The BT250LR cell line developed a transient adaption by increasing HER signalling. Eight new RTK candidates were discovered, but their role in lapatinib resistance required further validation. This study suggested a novel strategy of drug combination between L+P in HER2-targeted therapy, which is promising for future investigation. It also uncovered new directions in RTK studies for their roles in lapatinib resistance.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
2秒前
2秒前
3秒前
Jio-PPx完成签到,获得积分10
4秒前
5秒前
苏小咩发布了新的文献求助10
5秒前
5秒前
王禹垚发布了新的文献求助10
6秒前
袋袋发布了新的文献求助10
6秒前
7秒前
NY发布了新的文献求助10
7秒前
lyj发布了新的文献求助10
7秒前
所所的应助被qd采纳,获得10
8秒前
9秒前
科研通AI6.3的应助被lmy采纳,获得10
9秒前
zhudaxia完成签到,获得积分10
11秒前
11秒前
11秒前
花痴的手套完成签到 ,获得积分10
11秒前
麦粑块发布了新的文献求助10
12秒前
小牛牛发布了新的文献求助10
12秒前
12秒前
14秒前
INT发布了新的文献求助10
15秒前
hyy发布了新的文献求助30
15秒前
研友_VZG7GZ的应助被李瑞程采纳,获得10
15秒前
小蘑菇的应助被醉熏的寄松采纳,获得10
16秒前
我是谁的应助被醉熏的寄松采纳,获得50
16秒前
zhudaxia发布了新的文献求助30
16秒前
领导范儿的应助被醉熏的寄松采纳,获得10
16秒前
慕青的应助被醉熏的寄松采纳,获得10
16秒前
无花果的应助被醉熏的寄松采纳,获得10
16秒前
Lucas的应助被醉熏的寄松采纳,获得10
16秒前
国服躺赢完成签到,获得积分10
16秒前
搜集达人的应助被醉熏的寄松采纳,获得10
17秒前
17秒前
桐桐的应助被醉熏的寄松采纳,获得30
17秒前
17秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183263
求助须知:如何正确求助?哪些是违规求助? 9572532
关于积分的说明 21826339
捐赠科研通 7780187
什么是DOI,文献DOI怎么找? 3433993
关于科研通互助平台的介绍 2558131
邀请新用户注册赠送积分活动 2480239